Introduction: Infections in Solid Organ Transplantation

Green, M.

doi:10.1111/ajt.12093

Cited by 121 publications

(91 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8,10,23,24 Traditionally, a greater number of infections are expected in the first 6 months of transplantation, a period in which immunosuppression is more intense. 25,26 However, it is interesting to note that patients included in this study had on average more than 5 years of transplantation.…”

Section: Discussionmentioning

confidence: 98%

Factors associated with hospital mortality in renal transplant patients admitted to the intensive care unit with acute respiratory failure

Silva

Freitas

Bafi

et al. 2017

Jornal Brasileiro De Nefrologia

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Factors associated with hospital mortality in renal transplant patients admitted to the intensive care unit with acute respiratory failure

Silva

Freitas

Bafi

et al. 2017

Jornal Brasileiro De Nefrologia

View full text Add to dashboard Cite

show abstract

“…alıcı: Altta yatan hastalığın şiddeti postoperatif morbidite ve mortalite ile doğrudan ilişkilidir (1) . Benzer şekilde kronik malnütrisyon ya da total parenteral nüt-risyon için kullanılan kateterler enfeksiyona artmış eğilim oluşturmaktadır.…”

Section: Nakil öNcesi Risklerunclassified

“…Pediatrik SON'da tüm bu risklere ek olarak genellikle erişkin organı kullanıldığından nakledilen organ boyutu ile ilişkili olarak anastamozda kaçak, tromboz ya da nekroz riski daha fazla olabilmektedir (3) . (1,4) . Kullanılan immunsüpresyon genellikle çocuklar-da erişkenlere göre daha yüksek düzeyde olabilmektedir.…”

Section: Nakil öNcesi Risklerunclassified

“…Valgansiklovir daha büyük çocuk-larda kullanımı uygun olacaktır (29) . AST IDCoP reh- (1) ya da erişkin hastalardaki gibi 3-6 ay boyunca valgansiklovir/İV gansiklovir 2-4 hafta valgansiklovir/İV gansiklovir ve ardışık izlem (1) 2 hafta valgansiklovir/İV gansiklovir ve ardışık izlem (1,2) ya da 3-4 ay valgansiklovir/İV gansiklovir 2 hafta valgansiklovir/İV gansiklovir ve ardışık izlem ( İki haftalık yeterli doz gansiklovir tedavi altında viral yükte artış olması durumunda, immunsüpresyon azaltılmalı ve direnç için genotipik test yapılmalıdır. Eğer hastada ciddi CMV hastalığı bulgusu var ise foskarnet tedavisine geçilmesi önerilmektedir.…”

Section: Pediatrik Böbrek Naklinde CMV öNleyici Tedavilerunclassified

“…Sitomegalovirüse bağlı akciğer enfeksiyonları akciğer ve kalpakciğer nakil alıcılarında daha sık ve daha ağır seyretmektedir. Tüm bunlara ek olarak transplante karaciğer CMV, HBV, HCV, HSV ve gibi viruslara nativ karaciğerden daha duyarlı olduğu bilinmektedir (1) .…”

Section: Introductionunclassified

See 2 more Smart Citations

Pediatric Solid Organ Transplant Infections

Törün¹,

Acar²,

Salman³

et al. 2016

Cocuk Dergisi

View full text Add to dashboard Cite

Case series of immunosuppressant drug interactions with flucloxacillin in heart transplant recipients

Gellatly

Yoo

Bergin

et al. 2019

Pharmacy Practice and Res

View full text Add to dashboard Cite

Background After heart transplantation, the International Society for Heart and Lung Transplantation (ISHLT) recommends calcineurin inhibitor (CNI)‐based immunosuppressant therapy with mycophenolate or a mammalian target of rapamycin (mTOR) inhibitor. Both CNIs and mTOR inhibitors are extensively metabolised by the cytochrome P450 enzyme pathway and are substrates of P‐glycoprotein (PGP), making drug interactions with these therapies an important consideration. Herein we report four cases of probable drug interactions between tacrolimus and everolimus with flucloxacillin in orthotopic heart transplant recipients. The effects were subtherapeutic immunosuppressant concentrations and cellular rejection. Clinical details All four heart transplant recipients received intravenous (IV) flucloxacillin for methicillin‐sensitive Staphylococcus aureus infections in conjunction with immunosuppression regimens containing everolimus and/or tacrolimus. Despite tacrolimus and everolimus dose adjustments, Grade 2R rejection was diagnosed in all four patients in association with subtherapeutic immunosuppressant concentrations. Outcomes A considerable increase in tacrolimus and everolimus trough concentrations was observed following cessation of IV flucloxacillin. The rise in concentrations occurred despite no change in or dose reductions of immunosuppressants. A possible mechanism for the interaction is via pregnane X receptor activation. Conclusion These cases provide support that flucloxacillin significantly reduces tacrolimus and everolimus trough concentrations in heart transplant recipients. Dosage adjustments and close monitoring of drug concentrations or consideration of alternative antimicrobial therapy is required to avoid episodes of rejection or adverse events upon commencing and ceasing flucloxacillin therapy.

show abstract

Introduction: Infections in Solid Organ Transplantation

Cited by 121 publications

References 29 publications

Factors associated with hospital mortality in renal transplant patients admitted to the intensive care unit with acute respiratory failure

Factors associated with hospital mortality in renal transplant patients admitted to the intensive care unit with acute respiratory failure

Pediatric Solid Organ Transplant Infections

Case series of immunosuppressant drug interactions with flucloxacillin in heart transplant recipients

Contact Info

Product

Resources

About